(MedPage Today) — Treatment with aficamten (Myqorzo) improved exercise capacity as well as health status and symptoms in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM) in a large, double-blind, placebo-controlled trial…
Source link
Nonobstructive Heart Enlargement Responds to Aficamten
